Drug Profile
Research programme: immunomodulating bacteria-based therapeutics - 4D Pharma
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator GT Biologics
- Developer 4D Pharma PLC
- Class Anti-inflammatories; Bacteria; Neuroprotectants
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autistic disorder
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Autistic-disorder in United Kingdom (PO)
- 18 Jan 2019 Preclinical trials in Autistic disorder in United Kingdom (PO) (4D Pharma pipeline, January 2019)
- 18 Jan 2019 Preclinical trials in Parkinson's disease in United Kingdom (PO)